Novavax Inc. logo

Novavax Inc. (NVAX)

Market Open
4 Jun, 16:24
NASDAQ (NGS) NASDAQ (NGS)
$
10. 51
+0.31
+2.9902%
$
1.8B Market Cap
- P/E Ratio
- Div Yield
2.51M Volume
-4.28 Eps
$ 10.2
Previous Close
Add Transaction
Day Range
10.1 10.56
Year Range
6.13 11.97
Want to track NVAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Novavax (NVAX) Outperforms Broader Market: What You Need to Know

Novavax (NVAX) Outperforms Broader Market: What You Need to Know

In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day.

Zacks | 1 year ago
Novavax (NVAX) Rises But Trails Market: What Investors Should Know

Novavax (NVAX) Rises But Trails Market: What Investors Should Know

In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day.

Zacks | 1 year ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day.

Zacks | 1 year ago
Wall Street Analysts Predict an 81.61% Upside in Novavax (NVAX): Here's What You Should Know

Wall Street Analysts Predict an 81.61% Upside in Novavax (NVAX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 1 year ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 year ago
Novavax (NVAX) Rises But Trails Market: What Investors Should Know

Novavax (NVAX) Rises But Trails Market: What Investors Should Know

In the latest trading session, Novavax (NVAX) closed at $8.55, marking a +0.53% move from the previous day.

Zacks | 1 year ago
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?

Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks | 1 year ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 year ago
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?

Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.

Zacks | 1 year ago
Loading...
Load More